Irbesartan And Hydrochlorothiazide
Product Images NDC 0054-0256

11 FDA label images from Hikma Pharmaceuticals Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Irbesartan And Hydrochlorothiazide (NDC 0054-0256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1a.jpg (Figure1a)

Figure1a.jpg (Figure1a)
A line graph showing the percentage of patients with systolic blood pressure (SBP) below 140 mmHg versus baseline SBP (mmHg). The legend differentiates results from various studies involving Irbesartan (Irb.), Hydrochlorothiazide (HCTZ), and their combination (Irb.-HCTZ) across Study V and Study VI, represented by different line styles and thicknesses.*
FDA Label Image

Figure1b.jpg (Figure1b)

Figure1b.jpg (Figure1b)
A line graph showing the percentage of patients with systolic blood pressure (SBP) below 130 mmHg plotted against baseline SBP (mmHg). The graph includes five distinct lines representing different studies with Irbesartan (Irb), Hydrochlorothiazide (HCTZ), or their combination (Irb.-HCTZ) from Study V and Study VI, each identified by different line styles in the legend.*
FDA Label Image

Figure2a.jpg (Figure2a)

Figure2a.jpg (Figure2a)
A line graph depicting % diastolic blood pressure (DBP) less than 90 mmHg versus baseline DBP (mmHg) for studies involving Irbesartan and Hydrochlorothiazide (Irb.-HCTZ) and Irbesartan (Irb.) alone from Study V and Study VI. Different line styles represent the combination therapy and individual components across the two studies.*
FDA Label Image

Figure2b.jpg (Figure2b)

Figure2b.jpg (Figure2b)
A line graph showing the percentage of diastolic blood pressure (DBP) less than 80 mmHg versus baseline DBP values (mmHg). Multiple lines represent different studies: Irbesartan and Hydrochlorothiazide combination (Irb.-HCTZ) from Study V and Study VI, Irbesartan (Irb.) alone from Study V and VI, and Hydrochlorothiazide (HCTZ) from Study V. The graph compares the outcomes across these treatment groups.*
FDA Label Image

Irbesartan-chem-structure (Irbesartan)

Irbesartan-chem-structure (Irbesartan)
Chemical structure of Irbesartan, an active ingredient in the product Irbesartan and Hydrochlorothiazide.*
FDA Label Image

Hydrochlorothiazide.jpg (Hydrochlorothiazide)

Hydrochlorothiazide.jpg (Hydrochlorothiazide)
Chemical structure of Hydrochlorothiazide, one of the active ingredients in the combination drug Irbesartan and Hydrochlorothiazide by Hikma Pharmaceuticals USA Inc. The structure shows a benzothiadiazine ring with chlorine, sulfonamide, and amine functional groups.*
FDA Label Image

Figure3.jpg (Image 01)

Figure3.jpg (Image 01)
A scatter plot with a fitted curve showing the relationship between Irbesartan Dose (mg/day) on the horizontal axis and a measurement in mmHg on the vertical axis. Data points spread mostly between 0 and 900 mg/day doses, with mmHg values ranging approximately from -4 to 12. The title and specific measurement type are not shown.*
FDA Label Image

Figure4.jpg (Image 02)

Figure4.jpg (Image 02)
A scatter plot with a fitted curve showing the relationship between Irbesartan dose (mg/day) on the x-axis and blood pressure change in mmHg on the y-axis. Data points and the curve illustrate an increasing, then leveling trend in mmHg reduction as the dose increases up to around 900 mg/day.*
FDA Label Image

Bl-150mg-12pt5mg-30s-c50000689-01-k02 (Image 03)

Bl-150mg-12pt5mg-30s-c50000689-01-k02 (Image 03)
Label for Irbesartan and Hydrochlorothiazide tablets, USP, 150 mg/12.5 mg strength. The label states each tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide, with a 30 tablet count. Distributed by Hikma Pharmaceuticals USA Inc., including storage instructions and a barcode.*
FDA Label Image

Bl-300mg-12pt5mg-30s-c50000687-01-k02 (Image 04)

Bl-300mg-12pt5mg-30s-c50000687-01-k02 (Image 04)
Label for Irbesartan and Hydrochlorothiazide tablets, USP, strength 300 mg/12.5 mg, in a package of 30 tablets. The label includes storage instructions, distributor information (Hikma Pharmaceuticals USA Inc.), and a barcode. The dosage form is tablets.*
FDA Label Image

Irbesartan And Hctz Tablets Usp\labels\bl-300-12pt5-90s.jpg (Bl 300 12pt5 90s)

Irbesartan And Hctz Tablets Usp\labels\bl-300-12pt5-90s.jpg (Bl 300 12pt5 90s)
Label for Irbesartan and Hydrochlorothiazide Tablets, USP 300 mg/12.5 mg, containing 90 tablets. The label includes the NDC number 0054-0255-22 and states storage instructions at 20° to 25°C. Distributed by Hikma Pharmaceuticals USA Inc. in Berkeley Heights, NJ. The label features a barcode and the Hikma logo in orange.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.